Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Onderzoek naar evaluatie van PRO-240 oogheelkundige oplossing in vergelijking met Optive®

9 november 2026 bijgewerkt door: Laboratorios Sophia S.A de C.V.

Fase I klinische studie om de veiligheid en verdraagbaarheid van PRO-240 oogheelkundige oplossing te evalueren in vergelijking met Optive® op het oogoppervlak van oftalmologisch en klinisch gezonde vrijwilligers

This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.

Studie Overzicht

Gedetailleerde beschrijving

The variables to be evaluated include:

Primary (safety):

- Incidence of unexpected advere events (AE's)

Secondary:

  • Changes in the ocular comfort index (OCI) score
  • Changes in intraocular pressure (IOP)
  • Changes in Best Corrected Visual Acuity (BCVA)
  • Adherence to treatment
  • Changes in tear film breakup time
  • Changes in fluorescein staining
  • Changes in lissamine green staining

Studietype

Ingrijpend

Inschrijving (Geschat)

32

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Having the ability to voluntarily give their signed informed consent.
  • Ophthalmologically and clinically healthy subjects.
  • Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.
  • Age ≥18 years.
  • Male or female gender.
  • Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO [Tubal Ligation]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form [ICF]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.
  • Best corrected visual acuity (BCVA) of 20/30 or better in both eyes.
  • Corneal staining ≤ grade I on the Oxford Scale.
  • Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.

Exclusion Criteria:

  • History of hypersensitivity to any of the components of the drugs under investigation.
  • Use of ophthalmic medications from any pharmacological group.
  • Use of medications by any other route of administration.
  • Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or antibiotics by any route of administration in the last 30 days.
  • History of eye surgery in the last 6 months.
  • Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.
  • In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.
  • Having participated in any clinical research study 30 days prior to inclusion in this study.
  • Having previously participated in this same study.
  • History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.
  • Diagnosis of glaucoma or ocular hypertension.
  • Known diagnosis of liver or heart disease.
  • Presenting active inflammatory or infectious disease at the time of entry into the study.
  • Presenting unresolved lesions or traumas at the time of entry into the study.
  • Having been subjected to non-ophthalmological surgical procedures in the last 3 months.
  • Being or having an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.
  • Active smoking (specified as the consumption of cigarettes regardless of the amount and frequency, 4 weeks prior to study inclusion and during the intervention period of this study).
  • Active alcoholism (specified as the consumption of alcoholic beverages, regardless of the amount and frequency, 72 hours prior to study inclusion and during the intervention period of this study).

Elimination Criteria:

  • Withdrawal of their consent to participate in the study (informed consent form).
  • Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
  • Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).
  • Non-tolerability or hypersensitivity to any of the drugs under investigation.
  • Adherence < 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: PRO-240
  • Propylene glycol 0.3% - Polyethylene glycol 400 0.5% - Glycerin 0.2%. Ophthalmic solution.
  • Dosage: 1 drop QID [4] (four times per day) for 7 days in both eyes.
  • Route of administration: Ophthalmic

-Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.

Actieve vergelijker: Optive®
  • Carboxymethylcellulose 0.5%; Glycerin 0.9%. Ophthalmic solution.
  • Dosage: 1 drop QID [4] (four times per day) for 7 days in both eyes.
  • Route of administration: Ophthalmic

- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of unexpected adverse events related to the interventions
Tijdsspanne: Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)

Any unfavorable medical condition affecting the subject after the administration of the investigation product, related to such intervention.

Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Changes in the Ocular Comfort Index score
Tijdsspanne: Days: 0 (Basal Visit), and 8 (Final Visit)

Changes in the Ocular Comfort Index (OCI) score in between interventions, the subjects will be questioned regarding this symptoms' incidence. The OCI contains 8 items (one positive and eight negative) that focus on discomfort associated with ocular surface disorders. Each of these questions has two parts, which separately inquire about the frequency and severity of symptoms.

The OCI score will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.

Days: 0 (Basal Visit), and 8 (Final Visit)
Adherence to treatment (adherence) Adherence to treatment (adherence)
Tijdsspanne: Days: 8 (Final Visit)

Adherence will be evaluated through the treatment record in the subject's diary.

Days: 8 (Final Visit)
Changes in Best Corrected Visual Acuity (BCVA)
Tijdsspanne: Days: 0 (Basal Visit) and 8 (Final Visit)

The BCVA will be evaluated through Snellen chart.

Days: 0 (Basal Visit) and 8 (Final Visit)
Changes in tear film breakup time
Tijdsspanne: Days: 0 (Basal Visit) and 8 (Final Visit)

The most common method for assessing stability is with fluorescein. The precorneal layer colored with fluorescein will change to less fluorescent or non-fluorescent regions. The time from the last blink to the appearance of these regions is the tear film breakup time.

Days: 0 (Basal Visit) and 8 (Final Visit)
Changes in intraocular pressure (IOP)
Tijdsspanne: Days: 0 (Basal Visit) and 8 (Final Visit)

Previous instillation of topical anesthetic, the IOP will be measured through a Goldmann tonometer during visits

Days: 0 (Basal Visit) and 8 (Final Visit)
Changes in the integrity of the ocular surface (fluorescein staining)
Tijdsspanne: Days: 0 (Basal Visit) and 8 (Final Visit)

Changes in the integrity of the ocular surface using fluorescein staining and evaluated through the Oxford scale. The standard Oxford scale for fluorescein staining has the following criteria: Grade 0- Equal to or less than panel A; Grade I- Equal to or less than panel B, greater than panel A; Grade II- Equal to or less than panel C, greater than panel B; Grade III- Equal or less than panel D, greater than panel C; Grade IV- Equal or less than panel E, greater than panel D; Grade V- Greater than panel E.

Days: 0 (Basal Visit) and 8 (Final Visit)
Changes in lissamine green staining of the conjunctival surface
Tijdsspanne: Days: 0 (Basal Visit) and 8 (Final Visit)

Direct observation with slit lamp, graded according to (changes in ocular surface staining using the Sjögren's International Collaborative Clinical Alliance [SICCA].)

Days: 0 (Basal Visit) and 8 (Final Visit)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

30 juli 2027

Primaire voltooiing (Geschat)

30 maart 2028

Studie voltooiing (Geschat)

30 april 2028

Studieregistratiedata

Eerst ingediend

12 april 2024

Eerst ingediend dat voldeed aan de QC-criteria

16 april 2024

Eerst geplaatst (Werkelijk)

19 april 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • SOPH240-0923/I

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren